The global market for PCOS is projected to have a considerable CAGR of around 4.0% during the forecast period. Polycystic ovary syndrome is a hormonal disorder observed in females of reproductive ages. The disorder causes the excessive production of hormones in the female body, which include testosterone or androgens, hormones that are primarily associated with the male reproductive system. PCOS includes a range of symptoms such as irregular menstrual cycle, trouble in getting pregnant, cyst formation in the ovaries, excessive body and facial hair, and pelvic pain, among others. Moreover, the early diagnosis of the disorder is highly recommended by the physicians, as untreated PCOS may often lead to high cholesterol, type-2 diabetes, heart disease, insulin resistance, and high blood pressure. Major factors contributing to the growth of the global polycystic ovary syndrome market include a sedentary lifestyle and faulty dietary habits and an increasing female obese population across the globe. Initiatives taken by the government and non-profit organizations to spread awareness regarding the early diagnosis of the disorder are significantly fueling the market growth.

Moreover, increasing genetic and hormonal disorder in the female population is a major cause for the increase of polycystic ovary syndrome patients across the globe. The cost associated with the treatment of PCOS is the major factor affecting the growth of the market. According to the National Institute of the Health report, the cost to the US healthcare system to identify and manage PCOS is approximately $4 billion annually. However, the lack of regulatory approved drugs for the treatment of PCOS and easy availability of generic and off-label drugs may restrain the growth of the global PCOS market. However, market players are focusing on the development of innovative and symptom-specific drugs that are expected to fuel market growth in the near future.

Impact of COVID-19 on Global PCOS Market

The COVID-19 pandemic negatively affected the global PCOS market. As lockdown was announced by the government of major economies due to which essentials services and transportation facilities were put on halt. On the other hand, many gynaecological procedures and nonessential treatments for PCOS were postponed. Even the new products and launches of products and drugs for the treatment of PCOS were canceled. This led to a decline in market growth. Besides, disruption in raw material supply from China was also witnessed during the pandemic, due to which the various drug development companies experienced major loss and fewer products in the pipeline. All these factors affected the market growth.

Segmental Outlook  

The global PCOS market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on drug type, the market is segmented into diuretics, insulin-sensitizing agents, antiandrogens, anti-depressants, ornithine decarboxylase inhibitors, anti-obesity, and oral contraceptive pills. Among these, the insulin-sensitizing agents hold a major share owing to the wide adoption of the drug for the treatment of insulin resistance, to prevent diabetes which is one of the major causes of PCOS. Based on the diagnosis, the market is further classified into ultrasound, pelvic exam, and blood test. Whereas, the treatment segment is categorized into ovarian wedge resection, laparoscopic ovarian drilling, and acupuncture. Similarly, based on distribution channels, the global PCOS market is segmented into hospital pharmacies, retail pharmacies (online and offline), and fertility clinics. 

Global PCOS Market Share by Treatment, 2020 (%)

Laparoscopic Ovarian Drilling is Expected to Dominate the PCOS Market

Based on treatment, laparoscopic ovarian drilling dominated the market and it is projected to grow at significant CAGR during the forecast period. The rising prevalence of polycystic ovarian syndrome is the major factor driving the growth of the market. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome. The increasing prevalence of PCOS creating the demand for advanced and cost-effective treatments such as laparoscopic ovarian drilling. Laparoscopic ovarian drilling is a surgical treatment that can trigger ovulation in women having PCOS and can destroy the parts of ovaries by electrocautery or a laser. Pregnancy success rates in the first year in women after ovarian drilling range surgery at around 50% according to the American Society for Reproductive Medicine. Due to these factors, the segment is expected to grow during the forecast period.

Regional Outlook 

Geographically, the global PCOS market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is projected to exhibit the fastest growth in the global PCOS market during the forecast period. This is due to the large pool of female obese population in the region, especially in China. The presence of a large patient pool, government awareness programs regarding the growing prevalence of PCOS, and advancement in cost-effective treatments for PCOS are the major factors driving the growth of the market during the forecast period. 

Global PCOS Market Growth, by Region 2021-2027

North America Holds the dominant Position in the Global PCOS market

Geographically, North America held the largest share in 2020, and it is projected to dominate the market during the forecast period. This is mainly owing to the rising prevalence of PCOS disorder, and the large presence of the obese female population. According to the CDC, in the US, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of Women. This increasing prevalence creating the strong demands for an effective treatment for PCOS. Moreover, high reimbursement policies by the government in the healthcare sector and awareness amongst the population regarding the early diagnosis of the disorder, and adoption of minimal invasive surgeries (MIS) are significantly contributing towards the market growth in the region.

Market Players Outlook

The key players in the global PCOS market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals, Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, FDA approvals, and geographical expansions to generated more revenue and to remain competitive in the market. For instance, in January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with Celmatix Inc., to develop multiple clinical candidates for the treatment of PCOS. Through this agreement, both companies contributed drug targets and a comprehensive set of high-quality technology platforms to develop innovative treatment options for PCOS. 

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Polycystic Ovary Syndrome (PCOS) market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.